NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Net Income Margin for the year ending December 31, 2023: -1,386.36%

NewAmsterdam Pharma Company N.V. Net Income Margin is -1,386.36% for the year ending December 31, 2023, a -6,190.12% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

NewAmsterdam Pharma Company N.V. Net Income Margin for the year ending December 31, 2022 was -22.04%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years